Pelosi joined more than 250 Senate and House Democrats ... to protect mifepristone access.
Will work to protect access to mifepristone.
Occurrences
Pelosi joined more than 250 Senate and House Democrats... in filing an amicus brief to the Supreme Court urging them to overturn a Fifth Circuit decision that would upend the FDA approval process and restrict access to mifepristone.
Evidence
legacy_unverified · Source version not recorded · locator unknown
On May 5, 2026, Pelosi’s office said she joined more than 250 Senate and House Democrats in filing an amicus brief to the Supreme Court urging it to overturn a Fifth Circuit decision that would restrict access to mifepristone. The release says the lawmakers argued that preserving evidence-based access to mifepristone, including by mail or retail pharmacy, is necessary to mitigate imminent harm.
legacy_unverified · Source version not recorded · locator unknown
Pelosi’s office said she joined more than 250 Senate and House Democrats in filing an amicus brief urging the Supreme Court to overturn a Fifth Circuit decision that would restrict access to mifepristone. The release said lawmakers argued that preserving evidence-based access to mifepristone, including by mail or retail pharmacy, was necessary to avoid imminent harm.
legacy_unverified · Source version not recorded · locator unknown
The Supreme Court filing supports applications to stay or vacate the Fifth Circuit order restricting mifepristone access, asks the Court to grant emergency relief, and lists Rep. Nancy Pelosi among the House amici.
legacy_unverified · Source version not recorded · locator unknown
The Supreme Court docket records the May 4 filing of the 259 Members of Congress amicus brief and a May 14 order granting a stay of the Fifth Circuit order pending appeal and possible certiorari.
Assessments
Pelosi directly worked to protect mifepristone access while serving in federal office by joining the 259-member congressional amicus brief asking the Supreme Court to stay or vacate the Fifth Circuit order restricting access, including mail and retail pharmacy access. The Supreme Court then granted the stay on May 14, 2026, preserving access while the case continued. Because the promise was framed as working to protect access, not permanently resolving all mifepristone litigation, this counts as fulfilled in the same term.
The promise was to work to protect access to mifepristone, and the evidence shows Pelosi took direct, documented action in office by joining a large congressional amicus brief urging the Supreme Court to preserve access, including by mail and retail pharmacy. Because the claim is framed as undertaking protective action rather than singlehandedly guaranteeing the final policy outcome, this constitutes delivery of the promise within the same term.
Pelosi took a clear, documented action toward the promise by joining an amicus brief urging the Supreme Court to preserve access to mifepristone. That shows active work to protect access during the relevant term. However, the evidence only establishes an advocacy effort, not that she herself secured or completed a policy outcome guaranteeing continued access. Because the promise is to work to protect access, her action supports meaningful progress, but without evidence of a completed protective outcome attributable to her, partial credit is the best fit.